|
1
|
Viau M, Renaud MC, Gregoire J,
Sebastianelli A and Plante M: Paraneoplastic syndromes associated
with gynecological cancers: A systematic review. Gynecol Oncol.
146:661–671. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Banach P, Suchy W, Dereziński P, Matysiak
J, Kokot ZJ and Nowak-Markwitz E: Mass spectrometry as a tool for
biomarkers searching in gynecological oncology. Biomed
Pharmacother. 92:836–842. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA:
Gynecologic Oncology Group: Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou YF: High intensity focused ultrasound
in clinical tumor ablation. World J Clin Oncol. 2:8–27. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
To SKY, Mak ASC, Fung Eva YM, Che CM, Li
SS, Deng W, Ru B, Zhang J and Wong AST: β-catenin downregulates
Dicer to promote ovarian cancer metastasis. Oncogene. 36:5927–5938.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mihanfar A, Fattahi A and Nejabati HR:
MicroRNA-mediated drug resistance in ovarian cancer. J Cell
Physiol. Jun 19–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuo YT, Chang TT, Muo CH, Wu MY, Sun MF,
Yeh CC and Yen HR: Use of complementary traditional chinese
medicines by adult cancer patients in Taiwan: A nationwide
population-based study. Integr Cancer Ther. June 1–2017.(Epub ahead
of print).
|
|
9
|
Singh N, Bansal Y, Bhandari R, Marwaha L,
Singh R, Chopra K and Kuhad A: Naringin reverses neurobehavioral
and biochemical alterations in intracerebroventricular
collagenase-induced intracerebral hemorrhage in rats. Pharmacology.
100:172–187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen R, Qi QL, Wang MT and Li QY:
Therapeutic potential of naringin: An overview. Pharm Biol.
54:3203–3210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jeon SM, Bok SH, Jang MK, Kim YH, Nam KT,
Jeong TS, Park YB and Choi MS: Comparison of antioxidant effects of
naringin and probucol in cholesterol-fed rabbits. Clin Chim Acta.
317:181–190. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jagetia GC and Reddy TK: Modulation of
radiation-induced alteration in the antioxidant status of mice by
naringin. Life Sci. 77:780–794. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajadurai M and Stanely Mainzen Prince P:
Preventive effect of naringin on lipid peroxides and antioxidants
in isoproterenol-induced cardiotoxicity in Wistar rats: Biochemical
and histopathological evidences. Toxicology. 228:259–268. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Wang C, Peng J, Liang J, Jin Y, Liu
Q, Meng Q, Liu K and Sun H: Naringin inhibits TNF-α induced
oxidative stress and inflammatory response in HUVECs via Nox4/NF-κB
and PI3K/Akt pathways. Curr Pharm Biotechnol. 15:1173–1182. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramalingayya GV, Nampoothiri M, Nayak PG,
Kishore A, Shenoy RR, Rao Mallikarjuna C and Nandakumar K: Naringin
and rutin alleviates episodic memory deficits in two differentially
challenged object recognition tasks. Pharmacogn Mag. 12 Suppl
1:S63–S70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao X, Lin W, Liang C, Zhang D, Yang F,
Zhang Y, Zhang X, Feng J and Chen C: Naringin rescued the
TNF-α-induced inhibition of osteogenesis of bone marrow-derived
mesenchymal stem cells by depressing the activation of NF-κB
signaling pathway. Immunol Res. 62:357–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang HY and Yang X: Proteases for cell
suicide: Functions and regulation of caspases. Microbiol Mol Biol
Rev. 64:821–846. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu G, Wang X, Wu S and Li Q: Involvement
of activation of PI3K/Akt pathway in the protective effects of
puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell
death. Neurochem Int. 60:400–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Linder M and Tschernig T: Vasculogenic
mimicry: Possible role of effector caspase-3, caspase-6 and
caspase-7. Ann Anat. 204:114–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Médoc M, Dhilly M, Matesic L, Toutain J,
Krause-Heuer AM, Delamare J, Fraser BH, Touzani O, Barré L,
Greguric I and Sobrio F: In vivo evaluation of radiofluorinated
caspase-3/7 inhibitors as radiotracers for apoptosis imaging and
comparison with [18F]ML-10 in a stroke model in the rat. Mol
Imaging Biol. 18:117–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zolota V, Gerokosta A, Melachrinou M,
Kominea A, Aletra C and Scopa CD: Microvessel density,
proliferating activity, p53 and bcl-2 expression in in situ
ductal carcinoma of the breast. Anticancer Res. 19:3269–3274.
1999.PubMed/NCBI
|
|
22
|
Takehara T, Liu X, Fujimoto J, Friedman SL
and Takahashi H: Expression and role of Bcl-xL in human
hepatocellular carcinomas. Hepatology. 34:55–61. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Cui J, Yu Q, Wu X, Pan A and Li L:
Evaluation of CCND1 amplification and CyclinD1 expression: Diffuse
and strong staining of CyclinD1 could have same predictive roles as
CCND1 amplification in ER positive breast cancers. Am J Transl Res.
8:142–153. 2016.PubMed/NCBI
|
|
24
|
Yamamoto K, Lee BJ, Li C, Dubois RL,
Hobeika E, Bhagat G and Zha S: Early B-cell-specific inactivation
of ATM synergizes with ectopic CyclinD1 expression to promote
pre-germinal center B-cell lymphomas in mice. Leukemia.
29:1414–1424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kandela I, Jin HY and Owen K:
Reproducibility Project: Cancer biology: Registered report: BET
bromodomain inhibition as a therapeutic strategy to target c-Myc.
Elife. 4:e070722015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin CY, Lovén J, Rahl PB, Paranal RM,
Burge CB, Bradner JE, Lee TI and Young RA: Transcriptional
amplification in tumor cells with elevated c-Myc. Cell. 151:56–67.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang E, Li W, Yin D, De W, Zhu L, Sun S
and Han L: c-Myc-regulated long non-coding RNA H19 indicates a poor
prognosis and affects cell proliferation in non-small-cell lung
cancer. Tumour Biol. 37:4007–4015. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu DW, Hsu NY, Wang YC, Lee MC, Cheng YW,
Chen CY and Lee H: c-Myc suppresses microRNA-29b to promote tumor
aggressiveness and poor outcomes in non-small cell lung cancer by
targeting FHIT. Oncogene. 34:2072–2082. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia B, Tian C, Guo S, Zhang L, Zhao D, Qu
F, Zhao W, Wang Y, Wu X, Da W, et al: c-Myc plays part in drug
resistance mediated by bone marrow stromal cells in acute myeloid
leukemia. Leuk Res. 39:92–99. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and
Fujii Y: Expression of survivin in esophageal cancer: Correlation
with the prognosis and response to chemotherapy. Int J Cancer.
95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mitrović Z, Ilić I, Aurer I, Kinda SB,
Radman I, Dotlić S, Ajduković R and Labar B: Prognostic
significance of survivin and caspase-3 immunohistochemical
expression in patients with diffuse large B-cell lymphoma treated
with rituximab and CHOP. Pathol Oncol Res. 17:243–247. 2011.
View Article : Google Scholar : PubMed/NCBI
|
